COHANCE

Price Chart

Risk-Adjusted Performance

COHANCE (COHANCE) Price Performance

COHANCE (COHANCE) trades on NSE in INR. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at INR361.20, down 7.52% from the previous close.

Over the past year, COHANCE has traded between a low of INR279.90 and a high of INR1108.80. The stock has lost 65.9% over this period. It is currently 67.4% below its 52-week high.

COHANCE has a market capitalization of $148.79B, with a price-to-earnings ratio of 76.94.

About COHANCE

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.